Select conditions we are targeting:
ARDS [Acute Respiratory Distress Syndrome]
Our lung drug will be the first to block the root cause of inflammation associated with ARDS
IBD [Inflammatory Bowel Disease]
Our IBD drug will block GI inflammation and eliminate its consequences.
DFU [Diabetic Foot Ucers]
Our drug for non-healing wounds will halt the inflammatory cascade and restore natural healing.
Restoring Natural Healing.
Recovering from injury and infection through the body’s inflammatory process is the norm, but sometimes inflammation can become uncontrolled. Unregulated inflammation is proven causal to several acute and chronic conditions and diseases. By boosting the body’s innate ability to regulate inflammation–the consequences of inflammation are eliminated, and tissues can heal normally.
Ceria Therapeutics develops innovative drug products for inflammatory disorders. We intend to transform lives by eliminating the consequences of inflammation and resolving disease itself.
LATEST NEWS
Funding
Ceria Therapeutics, Inc. Awarded a $2,000,000 SBIR Grant to Advance Development of a Novel Treatment for Non-healing Diabetic Foot Ulcers
Go to articleFunding
Ceria Therapeutics, Inc. Awarded a $3,800,000 DoD Contract to Advance Development of a Novel Treatment for Acute Lung Injuries
Go to articlePublication
Photopolymerized Zwitterionic Hydrogels with a Sustained Delivery of Cerium Oxide Nanoparticle-miR146a Conjugate Accelerate Diabetic Wound Healing
Go to articleCONTACT US
OUR ADDRESS
Ceria Therapeutics, Inc
1230 N Cherry Ave, BSRL 329
Tucson, AZ 85721